



Tetrahedron Letters 44 (2003) 1847-1849

Studies on uracils: synthesis of novel pyrido[2,3-d]pyrimidine oxides via ring transformation of isoxazolo[3,4-d]pyrimidine

P. J. Bhuyan,* H. N. Borah and R. C. Boruah

Medicinal Chemistry Division, Regional Research Laboratory, Jorhat 785006, Assam, India Received 28 October 2002; revised 3 January 2003; accepted 10 January 2003

Abstract—The reaction of isoxazolo[3,4-d]pyrimidine 1 and cyanoolefins 2 in the presence of triethylamine (Et₃N) as a catalyst afforded an unprecedented one-pot synthesis of biologically important pyrido[2,3-d]pyrimidine oxides 3 in excellent yields. © 2003 Elsevier Science Ltd. All rights reserved.

The importance of uracil and its annelated derivatives is well recognised by synthetic¹ as well as biological² chemists. Organic N-oxides are an important class of compounds that possess a wide range of biological activities.³ Readily available cyanoolefins are versatile reagents having diverse uses in organic synthesis.⁴ Utilizing these organic synthons, we studied their reactivity with 6-amino and 6-hydrazino uracils⁵ which involved electrophilic attack of the cyanoolefins on the amino and hydrazino uracils leading to the formation of pyrido[3,4-d]pyrimidines and pyrazolo[2,3-d]pyrimidines, respectively. In continuation of our studies on uracils⁶ we describe in this communication the results of reactions between isoxazolo[3,4-d]pyrimidine and cyanoolefins in the presence of triethylamine as a catalyst which affords an unprecedented one-pot synthesis of pyrido[2,3-d]pyrimidine oxides of biological importance in excellent yields (Scheme 1).

In our reaction, equimolar amounts of isoxazolo[3,4-d]-pyrimidine **1** (0.175 g, 1 mmol) and cyanoolefin **2a** (0.154 g, 1 mmol) in the presence of a catalytic amount of Et₃N (0.01 g) were refluxed in ethanol for 1 h. The solvent was removed under reduced pressure. The residue was chromatographed over silica gel using chloroform—ethyl acetate (50:50) as eluent. An 80% yield of the product (0.197 g) was obtained and identified as 6-cyano-7-aminopyrido[2,3-d]pyrimidine-2,4(1*H*,3*H*)-dione-8-oxide **3a**^{7a} from spectroscopic data and elemental analysis. Its IR spectrum exhibited sharp bands

Scheme 1.

Keywords: uracil; cyanoolefins; pyrido[2,3-d]pyrimidines.

^{*} Corresponding author. Fax: 0376 2370011; e-mail: drugs@csir.res.in

Scheme 2.

at 3250 cm⁻¹ (NH₂), 2220 (CN) and at 1625 (N⁺-O⁻). The ¹H NMR spectrum showed singlets at δ 8.20 for the aromatic protons. Similarly compound 1 was reacted with **2b–c**. When substituted cyanoolefins **2b–c** $(R^1 = p - CH_3OC_6H_4, p - ClC_6H_4)$ were employed, the same product 3a was obtained. The corresponding aldehydes 4 were detected (by TLC) as byproducts in the reaction mixtures. The reaction was generalised by reacting the isoxazolo[3,4-d]pyrimidine 1 with a number of α -cyanocinamates 2d-f and α -cyanocinamides 2g-hunder identical conditions. As expected the same product 3b7b was obtained from the reaction of the substituted cinamates 2d-f with 1. The aldehydes 4 eliminated were detected in each case. Similarly the α -cyanocinamides **2g**-h gave the same product **3c**^{7c} when reacted with 1.

A possible mechanism of the reaction is outlined in Scheme 2. The reaction occurs via initial keteneimine formation from the cyanoolefin in the presence of triethylamine. The keteneimine undergoes [4+2] cycloaddition with the isoxazolo[3,4-d]pyrimidine to give the adduct [A]. This is then attacked by ethanol and water molecules resulting in the rupture of the C–O bond to give the hydroxy intermediate [B], which eliminates an arylaldehyde and rearranges to afford the product 3.

Further study of this effective reaction is in progress. In conclusion, our results have demonstrated a very simple and effective ring transformation process leading to an important class of annulated uracils of biological significance.

References

- (a) Bradshaw, T. K.; Hutchison, D. W. Chem. Soc. Rev. 1977, 6, 43; (b) Lunt, E. In Comprehensive Organic Chemistry; Barton, D. H. R.; Ollis, W. D., Eds.; Pergamon Press: Oxford, 1979; Vol. 4, p. 493; (c) Brown, D. J. In Comprehensive Heterocyclic Chemistry; Katritzky, A. R.; Rees, C., Eds.; Pergamon Press: Oxford, 1984; Vol. 3, p. 57; (d) Sasaki, T.; Minamoto, K.; Suzuki, T.; Yamashita, S. Tetrahedron 1980, 36, 865; (e) Prajapati, D.; Bhuyan, P. J.; Sandhu, J. S. J. Chem. Soc., Perkin Trans. 1 1988, 607; (f) Bhuyan, P. J.; Borah, H. N.; Sandhu, J. S. J. Chem. Soc., Perkin Trans. 1 1999, 3083.
- (a) Marumoto, R.; Furukawa, Y. Chem. Pharm. Bull.
 1977, 25, 2974; (b) Griengl, R.; Wack, E.; Schwarz, W.; Streicher, W.; Rosenwirth, B.; De Clercq, E. J. Med. Chem. 1987, 30, 1199; (c) De Clercq, E.; Bernaerts, R. J. Biol. Chem. 1987, 262, 14905; (d) Jones, A. S.; Sayers, J. R.; Walker, R. T.; De Clercq, E. J. Med. Chem. 1988, 31, 268; (e) Mitsuya, H.; Yarchoan, R.; Broder, S. Science 1990, 249, 1533; (f) Pontikis, R.; Monneret, C. Tetrahedron Lett. 1994, 35, 4351.
- (a) Lehmann, C.; Gagneus, A.; Renk, E. Swiss Patent 1970, 496,721, 496,722, 497,444; (b) Gasco, A.; Mortarimi, V.; Serafino, A.; Calvino, R.; Menziani, E.; Reynaud, E. Farmaco. Ed. Sci. 1975, 30, 900; (c) Canon, W. N.; Gerzon, K. US Patent 1969, 3, 420,654.
- 4. For reviews and synthetic development, see: (a) Campaigne, E.; Schneller, S. W. *Synthesis* **1976**, 705; (b) Freeman, F. *Chem. Rev.* **1980**, *80*, 324; (c) Freeman, F. *Synthesis* **1981**, 925.

- (a) Gogoi, M.; Bhuyan, P. J.; Sandhu, J. S.; Baruah, J. N. J. Chem. Soc., Chem. Commun. 1984, 1549; (b) Bhuyan, P. J.; Boruah, R. C.; Sandhu, J. S. J. Org. Chem. 1990, 55, 568.
- (a) Bhuyan, P. J.; Lekhok, K. C.; Sandhu, J. S. *Tetrahedron Lett.* 1999, 40, 1793; (b) Bhuyan, P. J.; Borah, H. N.; Lekhok, K. C.; Sandhu, J. S. *J. Heterocycl. Chem.* 2001, 38, 491; (c) Bhuyan, P. J.; Borah, H. N.; Sandhu, J. S. *Tetrahedron Lett.* 2002, 43, 895.
- 7. (a) Compound **3a**. ($C_{10}H_9N_5O_3$) mp 218°C. ¹H NMR 90 MHz (CDCl₃+TFA) δ 3.30 (s, 3H), 3.48 (s, 3H), 8.20 (s, 1H). IR 3250, 2200, 1700, 1625, cm⁻¹. MS 247 M⁺. CHN

analyses calcd: C, 48.58; H, 3.64; N, 28.34; found: C, 48.45; H, 3.61; N, 28.23%; (b) Compound **3b**. ($C_{12}H_{11}N_4O_5$) mp 205°C. ¹H NMR 90 MHz (CDCl₃+ TFA) δ 1.41 (t, 3H), 3.35 (s, 3H), 3.66 (s, 3H), 4.3 (q, 2H), 8.10 (s, 1H). IR 3250, 1710, 1695, 1620 cm⁻¹. MS 294 M⁺. CHN analyses calcd: C, 48.98; H, 4.76; N, 19.05; found: C, 48.79; H, 4.72; N, 18.75%; (c) Compound **3c**. ($C_{10}H_{11}N_5O_4$) mp 212°C. ¹H NMR 90 MHz (CDCl₃+ TFA) δ 3.10 (s, 3H), 3.44 (s, 3H), 8.00 (s, 1H). IR 3250, 1700, 1675, 1615 cm⁻¹. MS 265 M⁺. CHN analyses calcd: C, 45.28; H, 4.15; N, 26.41; found: C, 45.12; H, 4.11; N, 26.20%.